Physician profile
Rony Ninan
NPI 1750526182
$15,575.55
in general payments reported to CMS, 2019-2025
52 companies · $21.32 in 2025
The $21.32 reported for 2025 was less than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $9,348 · 2021: $2,214 · 2022: $2,322 · 2023: $395 · 2024: $175 · 2025: $21.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $591.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $8,494.99 | 2019-2021 | |
| Abbvie INC. | $973.82 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $610.25 | 2019-2023 | |
| Amgen INC. | $509.35 | 2019-2021 | |
| Acorda Therapeutics, INC | $505.14 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $348.78 | 2020-2023 | Nuplazid |
| Sk Life Science, INC. | $333.84 | 2020-2022 | |
| Abbott Laboratories | $315.49 | 2019-2024 | Infinity |
| Biohaven Pharmaceutical Holding Company LTD. | $266.10 | 2022 | |
| Ucb, INC. | $251.32 | 2020-2022 | |
| Amneal Pharmaceuticals LLC | $246.80 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $246.50 | 2021 | |
| Allergan, INC. | $203.50 | 2019-2022 | |
| Genzyme Corporation | $197.57 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $189.29 | 2020-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rony Ninan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.